1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Head and neck cancers

Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinoma

Technology appraisal guidance [TA661] Published: 25 November 2020

  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Evidence

Review and download supporting evidence. Includes the full guideline if available.

Supporting evidence

  • Evaluation report  
  • Appraisal consultation committee papers PDF 8.81 MB 25 November 2020  
  • Final appraisal determination committee papers PDF 2.36 MB 25 November 2020